Spironolactone Offers No CV Benefit in Dialysis Patients
In addition, the relatively high rates of hyperkalemia associated with the drug — despite a run-in period — limit its use, said lead investigator Michael Walsh, MD, PhD, Renal Research Program, Population Health Research Institute, Hamilton, Ontario, Canada, who presented the results at the 62nd European Renal Association Congress on June 6.
He added: 'Cardiovascular mortality remains very high' in these patients, at the 'somewhat astounding' rate of 11% per year in the current trial.
The ACHIEVE Trial
Previous trials have suggested that MRAs are perhaps the 'most promising therapies' in this space, Walsh noted. He and his colleagues undertook the Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE) trial to evaluate the efficacy and safety of spironolactone.
The study included patients (age, ≥ 45 y or ≥ 18 y with history of diabetes) with kidney failure receiving maintenance dialysis who were at risk of CV death.
All patients underwent an active run-in where they were prescribed open-label spironolactone 25 mg/day for at least 7 weeks with no dosing adjustments followed by a final eligibility assessment to ensure they were ≥ 80% adherent to the medication and that their serum potassium levels did not exceed 6.0 mmol/L.
After the run-in period, 2538 of the originally selected 3565 patients were randomized to either spironolactone 25 mg/day or matching placebo. Follow-up was at 3 months, 6 months, and then every 6 months after, assessing for outcomes, safety, drug adherence, and drug resupply. Unlike the run-in period, clinicians could reduce the dose to 25 mg/three times a week if appropriate.
The average age of the patients was approximately 62 years, roughly 37% were female, and the median time that the patients had been receiving dialysis was 2 years. The primary cause of kidney failure was diabetes, in just over 40% of patients, followed by hypertension/ischemia in slightly over 25%.
The trial was stopped early by the external safety and event monitoring committee for futility, meaning it did not reach the target number events, even after the target had been revised downward due to better-than-expected adherence.
Walsh stated that the trial did not reach its primary outcome, with no significant difference in rates of CV death or heart failure hospitalization between the spironolactone and placebo groups at a hazard ratio (HR) of 0.92 ( P = .35).
There was also no significant difference between the two treatments when stratifying the patients by sex, previous heart failure, previous coronary artery disease, and the length of time they had been receiving dialysis.
Further analysis indicated there was no benefit from spironolactone over placebo when looking at cardiac and vascular deaths separately and when considering first and total heart failure hospitalizations individually. However, spironolactone was associated with an increased risk of hyperkalemia, with 123 events in the spironolactone-treated group vs 80 in the placebo group (HR, 1.54; 95% CI, 1.07-2.22).
Walsh noted that, despite the strengths of its large size and the high rates of adherence, the trial is limited by having a low statistical power due to being stopped early, the use of a composite primary outcome, and the challenge in defining the patients most likely to benefit from the intervention.
Important Clinical Question
Session co-Chair Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, told Medscape Medical News that the study addressed an 'important clinical question,' and it is 'a pity that it didn't work out.'
He noted there have been numerous studies of CV disease in patients with chronic kidney disease who are not on dialysis, but 'there have been so few trials in dialysis patients,' and there consequently remains a lot to learn in this space.
As to what the current findings mean for MRAs in general in preventing CV outcomes, Gansevoort said he is 'not sure, because there are drug-specific differences between the first, second, and third generation, and we cannot extrapolate the findings with the first generation to the third.'
'Whether there ever will be a trial with the third generation in dialysis patients, I doubt, because industry will not want to fund it,' he continued, and so it will 'remain an important question.'
Christoph Wanner, MD, PhD, professor of medicine and head of the Division of Nephrology, University of Würzburg, Germany, noted that even if the number of patients in the trial were increased to 4000 or 5000 it would still not 'resolve the issue.'
'I think it's the end for MRAs in dialysis,' he told Medscape Medical News , and 'we have to think about what's going wrong in dialysis patients.'
'We started with statins. They didn't work. Hemodialysis/ hemodiafiltration does work, but drugs do not work. Why is this the case? What's going on? Did we design the right trials?' Wanner continued, 'I think this is still a [relevant research] question, but at the moment, with the ACHIEVE trial, the story of MRAs in dialysis is coming to an end.'
'Everyone who deals with dialysis patients realizes there is an excess of mortality, despite advancements in the technology of dialysis over the last 50 years,' noted Walsh at the start of his presentation.
He continued that there have been reductions in deaths from atheromatous CV disease among patients receiving dialysis for kidney failure, but 'importantly, the other kinds of reasons, including non-atheromatous cardiovascular disease, remain extremely high,' accounting for approximately 40% of all deaths in these patients.
'Trying to understand why there is such a high risk of cardiovascular death has been challenging,' Walsh added.
ACHIEVE was funded by grants from the Canadian Institutes of Health Research (Canada), the Medical Research Future Fund (Australia), the Health Research Council (New Zealand), the British Heart Foundation (United Kingdom), the Population Health Research Institute (Canada), St. Joseph's Healthcare Hamilton Division of Nephrology (Canada), Accelerating Clinical Trials (Canada), the CanSOLVE CKD Network (Canada), and the Department of Medicine, Dalhousie University (Canada).
No relevant financial relationships declared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
'Silent killer': the science of tracing climate deaths in heatwaves
A heatwave scorching Europe had barely subsided in early July when scientists published estimates that 2,300 people may have died across a dozen major cities during the extreme, climate-fuelled episode. The figure was supposed to "grab some attention" and sound a timely warning in the hope of avoiding more needless deaths, said Friederike Otto, one of the scientists involved in the research. "We are still relatively early in the summer, so this will not have been the last heatwave. There is a lot that people and communities can do to save lives," Otto, a climate scientist at Imperial College London, told AFP. Heat can claim tens of thousands of lives during European summers but it usually takes months, even years, to count the cost of this "silent killer". Otto and colleagues published their partial estimate just a week after temperatures peaked in western Europe. While the underlying methods were not new, the scientists said it was the first study to link heatwave deaths to climate change so soon after the event in question. Early mortality estimates could be misunderstood as official statistics but "from a public health perspective the benefits of providing timely evidence outweigh these risks," Raquel Nunes from the University of Warwick told AFP. "This approach could have transformative potential for both public understanding and policy prioritisation" of heatwaves, said Nunes, an expert on global warming and health who was not involved in the study. - Big deal - Science can show, with increasing speed and confidence, that human-caused climate change is making heatwaves hotter and more frequent. Unlike floods and fires, heat kills quietly, with prolonged exposure causing heat stroke, organ failure, and death. The sick and elderly are particularly vulnerable, but so are younger people exercising or toiling outdoors. But every summer, heat kills and Otto -- a pioneer in the field of attribution science -- started wondering if the message was getting through. "We have done attribution studies of extreme weather events and attribution studies of heatwaves for a decade... but as a society we are not prepared for these heatwaves," she said. "People think it's 30 (degrees Celsius) instead of 27, what's the big deal? And we know it's a big deal." When the mercury started climbing in Europe earlier this summer, scientists tweaked their approach. Joining forces, Imperial College London and the London School of Hygiene & Tropical Medicine chose to spotlight the lethality -- not just the intensity -- of the heat between June 23 and July 2. Combining historic weather and published mortality data, they assessed that climate change made the heatwave between 1C and 4C hotter across 12 cities, depending on location, and that 2,300 people had likely perished. But in a notable first, they estimated that 65 percent of these deaths -- around 1,500 people across cities including London, Paris, and Athens -- would not have occurred in a world without global warming. "That's a much stronger message," said Otto. "It brings it much closer to home what climate change actually means and makes it much more real and human than when you say this heatwave would have been two degrees colder." - Underestimated threat - The study was just a snapshot of the wider heatwave that hit during western Europe's hottest June on record and sent temperatures soaring to 46C in Spain and Portugal. The true toll was likely much higher, the authors said, noting that heat deaths are widely undercounted. Since then Turkey, Greece and Bulgaria have suffered fresh heatwaves and deadly wildfires. Though breaking new ground, the study has not been subject to peer review, a rigorous assessment process that can take more than a year. Otto said waiting until after summer to publish -- when "no one's talking about heatwaves, no one is thinking about keeping people safe" -- would defeat the purpose. "I think it's especially important, in this context, to get the message out there very quickly." The study had limitations but relied on robust and well-established scientific methodology, several independent experts told AFP. Tailoring this approach to local conditions could help cities better prepare when heatwaves loom, Abhiyant Tiwari, a health and climate expert who worked on India's first-ever heat action plan, told AFP. "I definitely see more such studies coming out in the future," said Tiwari from NRDC India. Otto said India, which experiences tremendously hot summers, was a "prime candidate" and with a template in place it was likely more studies would soon follow. np/klm/cw/tc
Medscape
34 minutes ago
- Medscape
How Music Therapy Rivals Opioids in Pain Relief
Tango, a rhythmic partner dance that enhances balance and coordination, can help ease the symptoms of Parkinson's disease. Choral singing, which combines vocal training and social interaction, may reduce depression in individuals with dementia. Music therapy has been shown to support stroke recovery by improving speech disorders. Many clinics in Germany have incorporated music therapy to address mental and physical health conditions. 'There is good evidence of effectiveness,' said Lutz Neugebauer, PhD, chairman of the German Music Therapy Society and co-organiser of the 13th European Music Therapy Congress, themed 'Bridges,' during an online press briefing. He noted that since Germany last hosted an international music therapy congress in 1996, nearly 9000 music therapy-related articles have been published in PubMed, including 1500 randomised controlled trials and 360 systematic reviews and meta-analyses. Germany's clinical guidelines on dementia, which reflect the highest level of evidence-based medical recommendations, endorse music therapy to ease symptoms such as anxiety, restlessness, and apathy. Music therapy is also included in 37 national clinical guidelines in Germany published by the Association of Scientific Medical Societies, 29 of which follow the country's highest standard for evidence-based care. 'There is an impressive wealth of evidence,' said Sabine C. Koch, PhD, professor of empirical research in the arts therapies at Alanus University of Arts and Social Sciences in Alfter, Germany. She outlined the conditions under which music therapy can complement psychotherapy or pharmacotherapy and its effectiveness. A recent meta-analysis of the effects of arts-based interventions in the treatment and management of noncommunicable diseases included 150 systematic reviews encompassing 3885 randomised controlled trials. 'The results particularly support music and dance therapy,' said Koch. The authors reported small-to-moderate effects for neurologic disorders (standardised mean difference [SMD] = 0.40; 95% CI, 0.30-0.50) and moderate effects for cancer (SMD = 0.52), cardiovascular disease (SMD = 0.52), mental illness (SMD = 0.53), and chronic respiratory disease (SMD = 0.76). However, most of these reviews had low methodologic quality. Still, the authors concluded that 'arts-based interventions may be a valuable addition to traditionally first-line treatments.' Clinical Benefits Music therapy has been well studied in the context of chronic pain and pain management in patients with advanced cancer. 'The overall effect is comparable to opioids, but without unwanted side effects,' Koch said. Music therapy also improves sleep and helps reduce fatigue, anxiety, and depression. Among newborns, music therapy has been shown to improve oxygen saturation, heart and respiratory rates, sleep duration, body temperature, and systolic and diastolic blood pressure. In premature infants, it also supports the development of a functional brain. Studies have shown positive effects on cardiorespiratory function, pain scores, oxygen saturation, and sleep duration, even during sleep. 'Music therapy helps these children reduce stress and recover,' said Koch. Neugebauer added that in premature infants, music therapy also strengthens the parent-child bond, 'one of the key indicators for better development after a difficult start in life.' Music therapy supports speech development in children with developmental delays. 'Music therapy is particularly effective for adolescents and young adults who have experienced trauma such as domestic violence, during migration, or war,' Neugebauer said. 'It enables expression beyond the spoken word and bridges language barriers.' He added that music therapy is often the first-choice approach for individuals struggling to communicate through speech, including those with disabilities. Oncology and Palliative Use Koch reported that music therapy has shown significant benefits for people with cancer, including reduced anxiety, depression, pain, fatigue, heart rate, and blood pressure. 'The effect is strong and significant,' she said, noting that the outcomes are comparable to those seen with cognitive-behavioural therapy. Music therapy promotes relaxation and reduces fatigue during palliative care. 'Music therapy is an effective treatment with a low dropout rate and improves the well-being of terminally ill patients,' said Koch. 'In treating depression and anxiety, it often matches the efficacy of cognitive-behavioural therapy.' Access Barriers According to Neugebauer, music therapy is an established part of inpatient care for anxiety, depression, substance use disorders, and the consequences of social isolation. However, music therapy remains excluded from outpatient reimbursements for health insurers. 'This urgently needs to change, particularly in vulnerable groups who depend on this therapy,' he said. Despite strong scientific evidence and positive clinical experience, calls to establish music therapy as a standard outpatient service are yet to be addressed at the political level, as Neugebauer noted. A 2011 report by Christine Bergmann, a former commissioner for the investigation of child sexual abuse, called for outpatient music therapy to be covered by health insurance. In 2019, the German Institute for Quality and Efficiency in Health Care reported that access to outpatient treatment remains unequal, with only higher-income individuals being able to afford it. 'In a healthcare system that prioritises outpatient over inpatient care, access to music therapy must be guaranteed for all patients — including in outpatient settings and health insurers must be required to cover the cost,' Neugebauer emphasised.
Yahoo
2 hours ago
- Yahoo
Bone-Eating Worms Have Lurked in The Ocean For 100 Million Years
Not content with a diet of old leaves, some worm species actually eat bones. A new study has now traced the ancient ancestors of these bone-burrowers back through 100 million years of evolution. Deep in the ocean, bone-eating worms from the genus Osedax feast on the carcasses of whales, sucking up fats and proteins from the skeletons. And it looks like they've been doing so for a while now. By scanning fossils to look for traces of bone-eating behavior, researchers from University College London (UCL) and the Natural History Museum in the UK have been able to identify seven new types of worm from the Cretaceous period. There would've been no whale on the menu at that time, but traces left behind by these worms were found in fossils of mosasaurs, ichthyosaurs, and plesiosaurs: the dominant marine reptiles of the time, now on show in museum exhibits. Related: "We haven't found anything else that makes a similar burrow to these animals," says paleontologist Sarah Jamison-Todd, from UCL. "As the ancient bores are so similar to modern Osedax species, and we don't have body fossils to contradict us, we assume that they were made by the same or a similar organism." "It shows that the bone-eating worms are part of a lineage that stretches back at least to the Cretaceous, and perhaps further. We can see how the diversity of bone-eating worms changes across millions of years." The team was able to build 3D models of 130 fossils without damaging them, through the use of computed tomography (CT) scans. Six fossils showed signs of burrows. That then led to the identification of seven new ichnospecies – species categorized based on traces in fossils, rather than direct remains of the creatures. Some of the boring patterns matched modern-day species, suggesting a surprising level of evolutionary stability across many millions of years. The researchers also used microscopic fragments around the fossils to date the bones and the worms that chewed through them. That placed them at at least 100 million years ago, meaning these creatures evolved much earlier than previously thought. "By using the remains of small organisms that make up the chalk itself, we were able to date the fossils to more precise time slices of the Cretaceous period," says Marc Jones, paleontologist at the Natural History Museum. There are plenty of other discoveries like this still waiting to be made, the researchers suggest – which could happen through further scans of ancient fossils as well as studies of the modern species living in the oceans today. Additional work looking at the genetics of the organisms living today could tell us more about the evolutionary history of these tiny creatures, though researchers will have to collect more samples and more data first. "There are many more examples of boring that haven't yet been named from both ancient and modern bone-eating worms," says Jamison-Todd. "In fact, some bores from the Cretaceous appear to be similar to ones that are still made today." "Finding out whether these burrows are made by the same species, or are an example of convergent evolution, will give us a much better idea of how these animals have evolved, and how they have shaped marine ecosystems over millions of years." The research has been published in PLOS ONE. Related News Ancient Voice Box Finally Reveals How Dinosaurs May Have Sounded Stunning Grand Canyon Fossils Reveal Evolution's Weird Experiments Neither Scales Nor Feathers: Bizarre Appendage Discovered on Reptile Fossil Solve the daily Crossword
